Novo Nordisk A/S (NYSE:NVO) Holdings Boosted by Fortis Capital Management LLC

Fortis Capital Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 45,888 shares of the company's stock after acquiring an additional 11,039 shares during the period. Fortis Capital Management LLC's holdings in Novo Nordisk A/S were worth $3,947,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Folketrygdfondet raised its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after purchasing an additional 40,313 shares during the period. Sustainable Growth Advisers LP raised its holdings in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after buying an additional 1,021,498 shares during the period. Raymond James Financial Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $404,910,000. WCM Investment Management LLC grew its stake in Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company's stock worth $345,588,000 after buying an additional 40,475 shares during the period. Finally, Amundi increased its position in shares of Novo Nordisk A/S by 26.4% in the fourth quarter. Amundi now owns 3,311,456 shares of the company's stock worth $283,615,000 after acquiring an additional 692,567 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Stock Down 2.2 %

Shares of NYSE:NVO traded down $1.55 during midday trading on Thursday, reaching $70.18. The company had a trading volume of 7,960,944 shares, compared to its average volume of 5,481,867. Novo Nordisk A/S has a one year low of $69.78 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $314.93 billion, a P/E ratio of 21.33, a PEG ratio of 0.90 and a beta of 0.42. The stock's fifty day moving average price is $82.78 and its 200-day moving average price is $99.75.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.